This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
respiratory syndrome | 8665 |
middle east | 6710 |
east respiratory | 6182 |
syndrome coronavirus | 5843 |
acute respiratory | 3296 |
severe acute | 2653 |
saudi arabia | 2465 |
cov infection | 2433 |
novel coronavirus | 1896 |
coronavirus infection | 1176 |
dromedary camels | 1167 |
respiratory tract | 1139 |
spike protein | 1110 |
human coronavirus | 978 |
public health | 914 |
immune response | 767 |
south korea | 725 |
coronavirus disease | 720 |
mers coronavirus | 675 |
sars coronavirus | 638 |
infectious diseases | 627 |
immune responses | 619 |
viral rna | 594 |
neutralizing antibodies | 575 |
clinical trials | 555 |
virus infection | 545 |
world health | 533 |
infection control | 531 |
doc id | 515 |
cord uid | 515 |
health care | 511 |
health organization | 506 |
influenza virus | 505 |
respiratory distress | 505 |
risk factors | 499 |
binding domain | 497 |
infected patients | 495 |
confirmed cases | 480 |
type i | 473 |
host cell | 471 |
human transmission | 470 |
viral replication | 456 |
lower respiratory | 442 |
animal models | 437 |
human coronaviruses | 435 |
distress syndrome | 435 |
mers outbreak | 434 |
innate immune | 427 |
coronavirus infections | 425 |
epithelial cells | 408 |
respiratory disease | 406 |
ebola virus | 403 |
incubation period | 395 |
dipeptidyl peptidase | 392 |
cov infections | 386 |
healthcare workers | 384 |
systematic review | 383 |
viral load | 380 |
cov spike | 377 |
mouse model | 374 |
upper respiratory | 373 |
critically ill | 367 |
united states | 365 |
pl pro | 364 |
pregnant women | 362 |
fatality rate | 361 |
infectious disease | 360 |
clinical characteristics | 357 |
mers patients | 355 |
amino acid | 350 |
coronavirus spike | 349 |
like protease | 344 |
converting enzyme | 344 |
receptor binding | 343 |
viral infections | 342 |
convalescent plasma | 340 |
clinical features | 340 |
rhesus macaques | 339 |
arabian peninsula | 335 |
severe respiratory | 332 |
hong kong | 331 |
novel human | 330 |
cl pro | 327 |
antiviral activity | 324 |
ill patients | 322 |
viral infection | 322 |
cov outbreak | 314 |
intensive care | 313 |
host cells | 312 |
cell entry | 307 |
cov cases | 302 |
spike glycoprotein | 299 |
lopinavir ritonavir | 296 |
cell lines | 294 |
neutralizing antibody | 292 |
clinical trial | 290 |
serum samples | 288 |
immune system | 285 |
viral entry | 282 |
respiratory failure | 279 |
respiratory illness | 279 |
infected cells | 273 |
disease control | 273 |
severe covid | 271 |
virus replication | 268 |
monoclonal antibodies | 266 |
mortality rate | 262 |
severe disease | 260 |
cell responses | 259 |
rna viruses | 259 |
case fatality | 258 |
cov cl | 254 |
patients infected | 254 |
mechanical ventilation | 253 |
confirmed mers | 251 |
respiratory viruses | 250 |
respiratory infections | 246 |
respiratory symptoms | 245 |
close contact | 242 |
mers cases | 242 |
control measures | 241 |
monoclonal antibody | 240 |
structural proteins | 240 |
disease severity | 238 |
animal model | 235 |
cov rbd | 234 |
cell culture | 233 |
cov pl | 233 |
respiratory syncytial | 231 |
closely related | 230 |
new coronavirus | 229 |
cytokine storm | 227 |
hospitalized patients | 227 |
syncytial virus | 221 |
rna polymerase | 218 |
care workers | 217 |
emerging infectious | 216 |
avian influenza | 215 |
infectious virus | 212 |
cov replication | 210 |
previously described | 208 |
symptom onset | 208 |
membrane fusion | 207 |
antibody responses | 207 |
viral shedding | 206 |
coronavirus hku | 206 |
coronavirus replication | 204 |
lung injury | 203 |
previous studies | 201 |
human infection | 200 |
functional receptor | 200 |
highly pathogenic | 200 |
chain reaction | 200 |
transgenic mice | 198 |
polymerase chain | 198 |
cov patients | 198 |
vaccinia virus | 197 |
may also | 196 |
influenza viruses | 195 |
nk cells | 193 |
amino acids | 192 |
dromedary camel | 189 |
tg mice | 187 |
dendritic cells | 185 |
descriptive study | 184 |
hospital outbreak | 183 |
infection prevention | 183 |
vero cells | 183 |
sars patients | 183 |
viral loads | 182 |
human cases | 182 |
human respiratory | 182 |
cov rna | 181 |
care unit | 180 |
inflammatory cytokines | 179 |
vaccine development | 178 |
virus entry | 177 |
gene expression | 174 |
target cells | 173 |
united arab | 171 |
clinical signs | 170 |
bat coronavirus | 169 |
arab emirates | 169 |
recent study | 168 |
severe pneumonia | 168 |
antiviral drugs | 167 |
i interferon | 166 |
human monoclonal | 166 |
statistically significant | 165 |
arabia middle | 165 |
specific antibodies | 164 |
nucleic acid | 164 |
host immune | 164 |
coronavirus pneumonia | 163 |
tract infections | 162 |
cov transmission | 162 |
ace receptor | 162 |
cohort study | 162 |
mg kg | 160 |
cell line | 160 |
present study | 158 |
cov strains | 158 |
mers cov | 158 |
sars outbreak | 157 |
mg ml | 157 |
vaccine candidates | 157 |
spectrum antiviral | 157 |
cleavage sites | 156 |
hepatitis virus | 156 |
performed using | 155 |
reverse transcription | 155 |
emerging human | 154 |
clinical course | 154 |
nucleocapsid protein | 153 |
associated coronavirus | 153 |
crystal structure | 152 |
cov infected | 152 |
protease inhibitors | 150 |
important role | 150 |
virus disease | 148 |
secondary cases | 148 |
accessory proteins | 147 |
weight loss | 147 |
time reverse | 147 |
bat coronaviruses | 145 |
mouse models | 145 |
nosocomial transmission | 145 |
inhibitory activity | 145 |
renal failure | 144 |
index case | 144 |
corona virus | 144 |
coronavirus associated | 143 |
global health | 143 |
spike proteins | 143 |
within days | 140 |
protease inhibitor | 140 |
human mers | 139 |
dependent rna | 139 |
direct contact | 138 |
open reading | 138 |
family cluster | 138 |
therapeutic options | 138 |
immune cells | 137 |
another study | 137 |
controlled trial | 136 |
clinical symptoms | 136 |
viral genome | 136 |
antibody response | 136 |
significantly higher | 136 |
common cold | 135 |
social media | 135 |
hand hygiene | 134 |
cov antibodies | 134 |
infectious bronchitis | 133 |
cases reported | 133 |
stranded rna | 133 |
respiratory infection | 132 |
zika virus | 132 |
innate immunity | 132 |
cov plpro | 132 |
cov clpro | 131 |
phylogenetic analysis | 130 |
human dpp | 130 |
genome sequence | 128 |
cell surface | 128 |
cell fusion | 128 |
antibody titers | 128 |
index patient | 127 |
healthcare facilities | 126 |
tract infection | 126 |
vaccine candidate | 126 |
room temperature | 125 |
human ace | 125 |
bat origin | 125 |
clinical manifestations | 125 |
large number | 123 |
nk cell | 123 |
phase i | 123 |
authors declare | 122 |
high mortality | 122 |
lung tissue | 122 |
cellular immune | 122 |
mouse hepatitis | 122 |
tested positive | 121 |
west nile | 121 |
type ii | 120 |
health literacy | 120 |
acute lung | 120 |
serine protease | 120 |
common marmoset | 119 |
person transmission | 119 |
coronavirus outbreak | 119 |
antiviral drug | 119 |
data collection | 119 |
severe cases | 118 |
transmission dynamics | 118 |
control group | 118 |
risk perception | 118 |
high levels | 118 |
tissue culture | 117 |
emergency room | 117 |
case definition | 116 |
first case | 116 |
antiviral response | 115 |
increased risk | 115 |
observational study | 115 |
viral proteins | 114 |
emerging coronaviruses | 114 |
nipah virus | 113 |
contact tracing | 113 |
high risk | 113 |
human population | 113 |
infl uenza | 112 |
hajj pilgrims | 112 |
common marmosets | 112 |
close contacts | 112 |
one study | 112 |
cleavage site | 112 |
infected mice | 111 |
reported cases | 111 |
time rt | 111 |
based vaccine | 111 |
care facilities | 111 |
inflammatory response | 111 |
healthcare settings | 111 |
described previously | 110 |
porcine epidemic | 110 |
clinical studies | 110 |
protective equipment | 109 |
coronavirus oc | 109 |
coronavirus receptor | 109 |
modified vaccinia | 109 |
animal species | 109 |
human airway | 109 |
dccov uae | 108 |
virus infections | 108 |
mice infected | 108 |
household contacts | 108 |
disease outbreak | 108 |
protective immunity | 107 |
bronchitis virus | 107 |
rbd vaccine | 106 |
coronavirus middle | 106 |
respiratory coronavirus | 106 |
serological study | 106 |
human betacoronavirus | 106 |
sore throat | 106 |
clinical outcomes | 106 |
organ failure | 105 |
retrospective cohort | 105 |
disaster response | 105 |
also known | 105 |
case report | 105 |
proinflammatory cytokines | 105 |
coronavirus mers | 104 |
lung pathology | 104 |
infected individuals | 104 |
several studies | 103 |
human covs | 103 |
personal protective | 103 |
two cases | 103 |
sialic acid | 102 |
nasal swabs | 102 |
immunodeficiency virus | 102 |
study showed | 102 |
human infections | 102 |
genomic characterization | 101 |
cells expressing | 101 |
antiviral agents | 101 |
cov nsp | 101 |
results showed | 101 |
rna synthesis | 100 |
human cells | 100 |
family members | 100 |
hemorrhagic fever | 100 |
epidemic diarrhea | 100 |
randomized controlled | 100 |
coronavirus nl | 100 |
therapeutic efficacy | 100 |
cell membrane | 99 |
sample size | 99 |
bat sars | 99 |
cause severe | 99 |
camel milk | 98 |
mycophenolic acid | 98 |
complete genome | 98 |
drug discovery | 98 |
peripheral blood | 98 |
intermediate host | 98 |
coronavirus papain | 97 |
adverse events | 97 |
randomized clinical | 97 |
mortality rates | 97 |
side effects | 97 |
clinical presentation | 96 |
respiratory diseases | 96 |
natural killer | 96 |
potential therapeutic | 96 |
suspected cases | 96 |
bat species | 96 |
vertical transmission | 96 |
cell cultures | 96 |
live attenuated | 95 |
two different | 95 |
chadox mers | 95 |
sequence identity | 95 |
retrospective study | 95 |
bovine coronavirus | 95 |
airway epithelial | 94 |
negative control | 94 |
murine coronavirus | 94 |
mers coronaviruses | 94 |
medical center | 94 |
imported case | 94 |
including sars | 93 |
adaptive immune | 93 |
rna virus | 93 |
dengue virus | 93 |
middle eastern | 93 |
infected camels | 93 |
gastrointestinal symptoms | 93 |
related coronavirus | 93 |
neutralizing monoclonal | 92 |
neutralizing activity | 92 |
healthcare worker | 92 |
endothelial cells | 92 |
united kingdom | 92 |
even though | 91 |
host range | 91 |
viral diseases | 91 |
ncov infection | 90 |
also found | 90 |
biosafety level | 90 |
previous study | 90 |
health authorities | 90 |
binding affinity | 90 |
reading frame | 90 |
disease progression | 90 |
infect dis | 89 |
rna genome | 89 |
dna vaccine | 89 |
broad spectrum | 89 |
human immunodeficiency | 89 |
terminal domain | 89 |
envelope protein | 88 |
cov vaccine | 88 |
risk factor | 88 |
virus ankara | 88 |
diabetes mellitus | 88 |
i ifn | 88 |
like particles | 88 |
study group | 88 |
clinical disease | 87 |
respiratory virus | 87 |
bat cov | 87 |
virus transmission | 87 |
rhesus macaque | 87 |
pathogenic coronaviruses | 86 |
general population | 86 |
emerging viruses | 86 |
coronavirus vaccine | 86 |
reproduction number | 86 |
total number | 86 |
serum antibodies | 85 |
cov virus | 85 |
chest ct | 85 |
therapeutic agents | 85 |
nonhuman primates | 85 |
transcription polymerase | 85 |
host response | 85 |
case series | 85 |
spike gene | 85 |
viral respiratory | 85 |
diarrhea virus | 85 |
main protease | 85 |
suspected mers | 85 |
laboratory testing | 85 |
one health | 84 |
transmissible gastroenteritis | 84 |
early stage | 84 |
confirmed case | 84 |
supplementary table | 84 |
intermediate hosts | 84 |
interferon beta | 84 |
icu admission | 84 |
infected pneumonia | 83 |
also observed | 83 |
cell receptor | 83 |
angiotensin converting | 83 |
pandemic influenza | 83 |
clinical management | 83 |
infected animals | 83 |
fusion protein | 83 |
electron microscopy | 83 |
genetic diversity | 83 |
previously reported | 82 |
active site | 82 |
days post | 82 |
treatment options | 82 |
antiviral therapy | 82 |
protective efficacy | 82 |
also reported | 82 |
wide range | 82 |
multiple organ | 82 |
endoplasmic reticulum | 82 |
bronchoalveolar lavage | 82 |
positive selection | 82 |
control study | 82 |
binding site | 81 |
drug repurposing | 81 |
cells infected | 81 |
recent studies | 81 |
time pcr | 80 |
life cycle | 80 |
viral clearance | 80 |
inflammatory responses | 80 |
alveolar damage | 80 |
well plates | 80 |
class i | 80 |
infect humans | 80 |
early stages | 80 |
respiratory droplets | 80 |
reverse genetics | 80 |
experimentally infected | 80 |
data suggest | 80 |
like coronavirus | 80 |
nervous system | 79 |
respiratory specimens | 79 |
nonhuman primate | 79 |
septic shock | 79 |
acquired pneumonia | 79 |
human cov | 79 |
nile virus | 79 |
viral titers | 79 |
first reported | 79 |
outbreak investigation | 79 |
structural basis | 79 |
expression levels | 79 |
results suggest | 79 |
severe mers | 78 |
newly discovered | 78 |
human neutralizing | 78 |
phase ii | 78 |
zoonotic transmission | 78 |
viral pneumonia | 78 |
viral particles | 78 |
risk assessment | 78 |
emergency department | 78 |
genome sequences | 78 |
genome sequencing | 77 |
media use | 77 |
among healthcare | 77 |
illness onset | 77 |
cov entry | 77 |
respiratory samples | 77 |
horseshoe bats | 77 |
cov pseudovirus | 77 |
two groups | 77 |
cov case | 77 |
adjuvanted rbd | 76 |
also showed | 76 |
cov genome | 76 |
fever virus | 76 |
least one | 76 |
adverse effects | 76 |
severe illness | 76 |
sars epidemic | 76 |
significant difference | 76 |
mers infection | 75 |
health emergency | 75 |
subunit vaccines | 75 |
respiratory viral | 75 |
news items | 75 |
mers case | 75 |
fruit bats | 75 |
lung disease | 75 |
higher risk | 75 |
high prevalence | 75 |
among patients | 74 |
nonstructural proteins | 74 |
macaque model | 74 |
mental health | 74 |
hydrogen bond | 74 |
cell response | 74 |
available data | 74 |
human disease | 74 |
epithelial cell | 74 |
improves outcome | 74 |
respiratory pathogens | 74 |
day post | 74 |
based vaccines | 73 |
factors influencing | 73 |
receptor ace | 73 |
medical staff | 73 |
cov pathogenesis | 73 |
live virus | 73 |
vaccine design | 73 |
cellular receptor | 73 |
infection among | 73 |
huh cells | 73 |
better understand | 73 |
case reports | 73 |
phylogenetic tree | 73 |
patients admitted | 73 |
study middle | 73 |
determine whether | 73 |
sars cases | 73 |
clinical data | 72 |
bronchial epithelial | 72 |
approved drugs | 72 |
supplementary material | 72 |
factors associated | 72 |
recombinant mva | 72 |
fatal cases | 71 |
pneumonia outbreak | 71 |
signaling pathways | 71 |
vitro studies | 71 |
tertiary care | 71 |
competing interests | 71 |
genetic recombination | 70 |
human primates | 70 |
dis doi | 70 |
interstitial pneumonia | 70 |
cov challenge | 70 |
laboratory confirmation | 70 |
first time | 70 |
creative commons | 70 |
mers outbreaks | 70 |
genomic rna | 70 |
human receptor | 70 |
comparative serological | 69 |
high viral | 69 |
orf ab | 69 |
pp ab | 69 |
cell epitopes | 69 |
discovered coronavirus | 69 |
highly conserved | 69 |
species transmission | 69 |
preventive measures | 69 |
plasma therapy | 69 |
virus shedding | 69 |
laboratory findings | 69 |
subunit vaccine | 69 |
study design | 69 |
humoral immune | 69 |
innate antiviral | 69 |
key role | 68 |
protein gene | 68 |
membrane oxygenation | 68 |
logistic regression | 68 |
coronavirus transmission | 68 |
body weight | 68 |
significant differences | 68 |
supportive care | 68 |
host innate | 68 |
cysteine protease | 68 |
cov isolates | 68 |
experimental infection | 68 |
critical care | 67 |
inhibit sars | 67 |
dry cough | 67 |
cov outbreaks | 67 |
results indicate | 67 |
combination therapy | 67 |
study reported | 67 |
like receptor | 67 |
antiviral effects | 67 |
primate model | 67 |
acid residues | 67 |
tcid ml | 67 |
airborne transmission | 67 |
linked immunosorbent | 67 |
medical conditions | 67 |
primary human | 67 |
cell types | 67 |
statistical significance | 66 |
new virus | 66 |
recombinant mers | 66 |
pcr assays | 66 |
specific igg | 66 |
nucleic acids | 66 |
antiviral treatment | 66 |
pandemic potential | 66 |
human dipeptidyl | 66 |
human metapneumovirus | 66 |
extracorporeal membrane | 66 |
southern china | 66 |
human lung | 66 |
natural reservoir | 66 |
influenza infection | 65 |
like proteases | 65 |
immunosorbent assay | 65 |
disease outbreaks | 65 |
macro domain | 65 |
plasma membrane | 65 |
inhibit mers | 65 |
human health | 65 |
taken together | 65 |
neutralization assay | 65 |
animal health | 65 |
reverse transcriptase | 64 |
viral spike | 64 |
sequence alignment | 64 |
coronavirus sars | 64 |
diffuse alveolar | 64 |
like virus | 64 |
coronavirus entry | 64 |
protein expression | 64 |
central nervous | 64 |
preventive behaviors | 64 |
future studies | 64 |
receptor recognition | 64 |
eastern respiratory | 64 |
healthcare personnel | 64 |
enveloped viruses | 64 |
viral pathogens | 64 |
data analysis | 64 |
comparative analysis | 64 |
time points | 63 |
human cell | 63 |
national health | 63 |
one patient | 63 |
saudi ministry | 63 |
better understanding | 63 |
institutional review | 63 |
cov receptor | 63 |
virus vaccine | 63 |
years old | 63 |
virus type | 63 |
bovine serum | 63 |
mers patient | 63 |
lymph nodes | 63 |
human igg | 63 |
virus titers | 63 |
single dose | 63 |
interferon alfa | 63 |
median age | 63 |
reading frames | 63 |
signaling pathway | 63 |
coronavirus neutralising | 63 |
membrane vesicles | 63 |
ge healthcare | 63 |
flow cytometry | 63 |
care settings | 62 |
animal reservoir | 62 |
bat covs | 62 |
host receptor | 62 |
neutralising serum | 62 |
review board | 62 |
recently emerged | 62 |
causative agent | 62 |
neutralising antibodies | 62 |
interim guidance | 62 |
western blot | 62 |
wild animals | 62 |
may contribute | 62 |
emerging viral | 62 |
rift valley | 62 |
fatality rates | 61 |
mean age | 61 |
social distancing | 61 |
evoked ca | 61 |
mild symptoms | 61 |
guinea pigs | 61 |
significantly lower | 61 |
lethal disease | 61 |
dependent manner | 61 |
older age | 61 |
coronavirus emc | 61 |
positive results | 61 |
protease tmprss | 61 |
coronavirus nsp | 61 |
findings suggest | 60 |
studies showed | 60 |
ca release | 60 |
relatively low | 60 |
coronavirus nucleocapsid | 60 |
potent neutralization | 60 |
tested negative | 60 |
potent inhibitor | 60 |
new human | 60 |
cov neutralizing | 60 |
necrosis factor | 60 |
confidence interval | 60 |
traditional chinese | 60 |
dpp receptor | 60 |
syndrome outbreak | 60 |
may provide | 60 |
mm tris | 59 |
positive control | 59 |
inhibitory effect | 59 |
related viruses | 59 |
rights reserved | 59 |
currently available | 59 |
transgenic mouse | 59 |
national institute | 59 |
infected patient | 59 |
new york | 59 |
similar results | 59 |
cytopathic effect | 59 |
valley fever | 59 |
basic reproduction | 59 |
cov epidemic | 59 |
camel mers | 59 |
igg antibodies | 59 |
receptor dpp | 59 |
phase iii | 59 |
emerging novel | 58 |
korean outbreak | 58 |
infectious peritonitis | 58 |
urgent need | 58 |
live mers | 58 |
west africa | 58 |
confirmed covid | 58 |
south korean | 58 |
molecular basis | 58 |
host factors | 58 |
protein kinase | 58 |
sars infection | 58 |
hospital transmission | 58 |
tract samples | 58 |
coronavirus study | 58 |
case patients | 58 |
urgently needed | 58 |
goat anti | 58 |
candidate vaccine | 58 |
specific cd | 58 |
feline infectious | 58 |
rhesus monkeys | 58 |
coronavirus rna | 58 |
ifn production | 58 |
chinese horseshoe | 58 |
single patient | 58 |
swab samples | 58 |
hubei province | 58 |
cov vaccines | 57 |
antiviral activities | 57 |
prospective study | 57 |
heptad repeat | 57 |
pseudotyped mers | 57 |
cov strain | 57 |
nosocomial outbreaks | 57 |
virus particles | 57 |
therapeutic strategies | 57 |
cov antibody | 57 |
fusion peptide | 57 |
coronavirus species | 57 |
mm nacl | 57 |
patient care | 57 |
human middle | 57 |
may occur | 57 |
emc strain | 57 |
pathogenic human | 57 |
analyzed using | 57 |
expression vector | 57 |
hendra virus | 57 |
like viruses | 57 |
like coronaviruses | 56 |
ace expression | 56 |
travel history | 56 |
mv vac | 56 |
abu dhabi | 56 |
care hospital | 56 |
treat covid | 56 |
outbreak associated | 56 |
avian coronaviruses | 56 |
copyright holder | 56 |
serially diluted | 56 |
nonstructural protein | 56 |
parainfluenza virus | 56 |
cell death | 56 |
samples collected | 56 |
day mortality | 56 |
medical records | 56 |
conformational changes | 56 |
severe middle | 55 |
see note | 55 |
saudi arabian | 55 |
hospital outbreaks | 55 |
enzymatic activity | 55 |
cov emc | 55 |
zoonotic coronaviruses | 55 |
asymptomatic cases | 55 |
adaptive evolution | 55 |
healthcare setting | 55 |
sporadic cases | 55 |
associated outbreak | 55 |
host species | 55 |
virus origins | 55 |
human sars | 55 |
like receptors | 55 |
rbv rifn | 55 |
spreading events | 55 |
potential risk | 55 |
diagnostic tests | 55 |
pathogenic coronavirus | 55 |
lessons learned | 55 |
cd dpp | 55 |
sense rna | 55 |
side chain | 55 |
negative pressure | 55 |
receptor cd | 54 |
mild respiratory | 54 |
first identified | 54 |
seasonal influenza | 54 |
fecal samples | 54 |
cov among | 54 |
secondary structure | 54 |
sars cov | 54 |
nasopharyngeal swab | 54 |
acute renal | 54 |
control practices | 54 |
novel virus | 54 |
bl mice | 54 |
angiotensin ii | 54 |
target cell | 54 |
ncov sars | 54 |
significantly reduced | 54 |
effective vaccine | 54 |
human milk | 54 |
current knowledge | 54 |
study also | 54 |
ic values | 54 |
inhibitors targeting | 53 |
patients may | 53 |
north america | 53 |
high level | 53 |
oral transmission | 53 |
probable bat | 53 |
cov causes | 53 |
gastroenteritis virus | 53 |
palm civets | 53 |
cardiovascular disease | 53 |
betacoronavirus lineage | 53 |
granted medrxiv | 53 |
blood samples | 53 |
severely ill | 53 |
health commission | 53 |
alveolar macrophages | 53 |
fatal case | 53 |
life technologies | 53 |
organ cultures | 53 |
author funder | 53 |
chinese medicine | 53 |
thermo fisher | 53 |
coronavirus using | 53 |
may play | 52 |
tumor necrosis | 52 |
viral pathogenesis | 52 |
recombination events | 52 |
family coronaviridae | 52 |
publicly available | 52 |
nlrp inflammasome | 52 |
clinical aspects | 52 |
domain complexed | 52 |
statistical analysis | 52 |
genomic characterisation | 52 |
disease prevention | 52 |
specific antibody | 52 |
disease caused | 52 |
copies ml | 52 |
fi gure | 52 |
fruit bat | 52 |
survival rates | 52 |
infections among | 52 |
guangdong province | 52 |
study clinical | 51 |
two patients | 51 |
transmission potential | 51 |
small molecule | 51 |
alveolar epithelial | 51 |
gene source | 51 |
fusion proteins | 51 |
camels middle | 51 |
global public | 51 |
rheumatoid arthritis | 51 |
virus challenge | 51 |
like symptoms | 51 |
disease course | 51 |
three times | 51 |
pcr testing | 51 |
patients received | 51 |
transmembrane serine | 51 |
small animal | 51 |
whole genome | 51 |
neutralization test | 51 |
hand washing | 51 |
viral antigen | 51 |
african green | 51 |
molecular docking | 51 |
cynomolgus macaques | 51 |
reported mers | 51 |
commonly used | 51 |
secondary infection | 50 |
fusion inhibitor | 50 |
throat swabs | 50 |
survival rate | 50 |
patients showed | 50 |
strand rna | 50 |
critical role | 50 |
coronavirus genome | 50 |
viral transmission | 50 |
lethal pneumonia | 50 |
studies using | 50 |
also detected | 50 |
mers transmission | 50 |
odds ratio | 50 |
effectively inhibit | 50 |
marburg virus | 50 |
current study | 50 |
proteolytic processing | 50 |
studies reported | 50 |
antiviral effect | 50 |
statistical analyses | 50 |
plaque assay | 50 |
clinical findings | 50 |
interspecies transmission | 50 |
antiviral compounds | 50 |
blood pressure | 50 |
human cd | 50 |
acid sequence | 50 |
infectious cdna | 50 |
case study | 50 |
current status | 50 |
pcr assay | 50 |
remains unclear | 50 |
twice daily | 50 |
zoonotic diseases | 50 |
study found | 50 |
national institutes | 50 |
computed tomography | 50 |
ii pneumocytes | 50 |
pediatric patients | 50 |
dub activity | 49 |
drug administration | 49 |
common symptoms | 49 |
based assays | 49 |
turnover intention | 49 |
natural reservoirs | 49 |
asymptomatic infection | 49 |
analysis showed | 49 |
candidate vaccines | 49 |
lung lesions | 49 |
clinically proven | 49 |
international committee | 49 |
receptor usage | 49 |
viral fusion | 49 |
inhibits mers | 49 |
icu patients | 49 |
reservoir host | 49 |
fetal bovine | 49 |
interferon response | 49 |
sars virus | 49 |
health concern | 49 |
multiple sequence | 49 |
antibody titer | 49 |
coronavirus antibodies | 49 |
drug targets | 49 |
virological analysis | 49 |
human populations | 49 |
relative humidity | 49 |
will help | 49 |
stem cells | 49 |
mammalian cells | 49 |
including deaths | 49 |
low levels | 49 |
cellular immunity | 49 |
first imported | 49 |
killer cells | 48 |
geographic distribution | 48 |
epidemiological data | 48 |
human macrophages | 48 |
lung tissues | 48 |
imported cases | 48 |
early phase | 48 |
available online | 48 |
data mining | 48 |
kidney disease | 48 |
data gaps | 48 |
infected rhesus | 48 |
vitro antiviral | 48 |
escherichia coli | 48 |
species barrier | 48 |
sequence analysis | 48 |
literature review | 48 |
immune evasion | 48 |
viral envelope | 48 |
global pandemic | 48 |
mice treated | 48 |
coronavirus vaccines | 48 |
control groups | 48 |
korea middle | 48 |
per well | 48 |
current situation | 48 |
small number | 48 |
calculated using | 48 |
previous reports | 48 |
including mers | 48 |
knowledge transfer | 48 |
interferon therapy | 48 |
corticosteroid treatment | 48 |
kidney cells | 48 |
spike receptor | 48 |
chikungunya virus | 47 |
coronavirus envelope | 47 |
risk communication | 47 |
potential role | 47 |
virus genome | 47 |
regression analysis | 47 |
indirect contact | 47 |
wild type | 47 |
novel middle | 47 |
generating procedures | 47 |
proteolytic cleavage | 47 |
ex vivo | 47 |
cytokine release | 47 |
mycophenolate mofetil | 47 |
vitro activity | 47 |
pulmonary disease | 47 |
molecular mechanisms | 47 |
high case | 47 |
structural studies | 47 |
observational studies | 47 |
patients treated | 47 |
virus spread | 47 |
structural protein | 47 |
influenza vaccine | 47 |
vaccine platform | 47 |
emerging pathogens | 47 |
buffered saline | 47 |
nasal swab | 47 |
may lead | 47 |
different types | 47 |
camel contact | 47 |
corticosteroid therapy | 47 |
causes lethal | 47 |
global spread | 47 |
hydrogen bonds | 47 |
illness caused | 47 |
epidemiological characteristics | 47 |
dpp expression | 47 |
primary cases | 47 |
plaque reduction | 47 |
investigation team | 47 |
affected countries | 46 |
two mers | 46 |
measured using | 46 |
chloroquine phosphate | 46 |
fisher scientific | 46 |
infected person | 46 |
luciferase activity | 46 |
transcription factor | 46 |
coronavirus isolated | 46 |
korea centers | 46 |
neu ac | 46 |
relatively high | 46 |
specific antiviral | 46 |
broad range | 46 |
epidemiological investigation | 46 |
comparative study | 46 |
predictive factors | 46 |
may cause | 46 |
may result | 46 |
fully human | 46 |
murine hepatitis | 46 |
emerging respiratory | 46 |
least two | 46 |
small molecules | 46 |
secondary infections | 46 |
arabia mers | 46 |
cell lysates | 46 |
jamaican fruit | 46 |
coronavirus causes | 46 |
cov antigen | 46 |
binding domains | 46 |
first cases | 46 |
cdna clone | 46 |
old man | 46 |
zoonotic origin | 46 |
feline coronavirus | 46 |
accessory protein | 46 |
among different | 46 |
tract specimens | 46 |
tissue tropism | 46 |
cov research | 46 |
syrian hamsters | 45 |
clinical presentations | 45 |
virus strain | 45 |
dna vaccines | 45 |
healthcare providers | 45 |
pipistrellus bat | 45 |
elevated levels | 45 |
entry receptor | 45 |
abattoir workers | 45 |
interferon production | 45 |
among humans | 45 |
host proteases | 45 |
acute kidney | 45 |
reactive protein | 45 |
first isolated | 45 |
em structure | 45 |
recognition receptors | 45 |
dpp binding | 45 |
syndrome middle | 45 |
see table | 45 |
ec values | 45 |
coronavirus fusion | 45 |
membrane protein | 45 |
clinical practice | 45 |
cov sequences | 45 |
causing severe | 45 |
disease transmission | 45 |
recombinant protein | 45 |
protective effect | 45 |
days prior | 45 |
high fatality | 45 |
abdominal pain | 45 |
times higher | 45 |
viral infectivity | 45 |
body temperature | 45 |
postexposure efficacy | 45 |
novel coronaviruses | 44 |
genome analysis | 44 |
recent years | 44 |
virus strains | 44 |
entry depends | 44 |
viral proteases | 44 |
study conducted | 44 |
symptomatic patients | 44 |
organ damage | 44 |
replication cycle | 44 |
igg antibody | 44 |
nsp nsp | 44 |
neutralization assays | 44 |
infection may | 44 |
significantly associated | 44 |
assessed using | 44 |
like sars | 44 |
mortality risk | 44 |
first mers | 44 |
based study | 44 |
mediated cell | 44 |
viral vectors | 44 |
recovered patients | 44 |
animal studies | 44 |
reduced viral | 44 |
novel viruses | 44 |
renal disease | 44 |
coronavirus outbreaks | 44 |
peer review | 44 |
neutralizing mabs | 44 |
viral disease | 44 |
specific human | 44 |
causes severe | 44 |
crispr cas | 44 |
pathological changes | 43 |
fold higher | 43 |
environmental factors | 43 |
widely used | 43 |
emerging coronavirus | 43 |
clinical improvement | 43 |
higher levels | 43 |
rapid generation | 43 |
nucleotide identity | 43 |
superspreading events | 43 |
ion channel | 43 |
syndrome virus | 43 |
vaccine efficacy | 43 |
first step | 43 |
higher mortality | 43 |
general public | 43 |
genbank accession | 43 |
dependent enhancement | 43 |
heart disease | 43 |
mucosal immunity | 43 |
graphpad prism | 43 |
adult patients | 43 |
virus isolation | 43 |
clinical description | 43 |
replacement therapy | 43 |
recent advances | 43 |
high affinity | 43 |
proven protease | 43 |
reservoir hosts | 43 |
fold increase | 42 |
lung lobes | 42 |
per day | 42 |
rbd protein | 42 |
i ifns | 42 |
positive samples | 42 |
past years | 42 |
emerging infection | 42 |
much higher | 42 |
immunized mice | 42 |
sea urchin | 42 |
transmembrane domain | 42 |
will also | 42 |
two studies | 42 |
contact investigation | 42 |
clinical study | 42 |
molecular weight | 42 |
potential treatment | 42 |
real time | 42 |
camel coronavirus | 42 |
emerging infections | 42 |
crucial role | 42 |
test results | 42 |
novel cov | 42 |
controlled trials | 42 |
transmission within | 42 |
study protocol | 42 |
infected people | 42 |
proprotein convertases | 42 |
domestic animals | 42 |
post infection | 42 |
cytokines chemokines | 42 |
emergency use | 42 |
neutralizing epitopes | 41 |
tissue damage | 41 |
newly identified | 41 |
viral antigens | 41 |
two weeks | 41 |
potent inhibitors | 41 |
two viruses | 41 |
i response | 41 |
mers pseudovirions | 41 |
acute phase | 41 |
new cases | 41 |
cysteine proteases | 41 |
effective treatment | 41 |
expressing mers | 41 |
healthcare system | 41 |
viral diagnosis | 41 |
cell membranes | 41 |
human beings | 41 |
medical care | 41 |
mice immunized | 41 |
zoonotic potential | 41 |
outbreak news | 41 |
symptomatic cases | 41 |
limited number | 41 |
made available | 41 |
viral titer | 41 |
oxygen saturation | 41 |
age groups | 41 |
treatment strategies | 41 |
mononuclear cells | 41 |
several countries | 41 |
reproductive number | 41 |
molecule inhibitors | 41 |
new insights | 41 |
tract disease | 41 |
might also | 41 |
multiorgan failure | 41 |
included studies | 41 |
recombinant virus | 41 |
using different | 41 |
encephalitis virus | 41 |
emerged novel | 41 |
environmental conditions | 41 |
safety profile | 41 |
coronavirus nonstructural | 41 |
kidney injury | 41 |
attack rate | 41 |
atypical pneumonia | 41 |
rapid response | 41 |
median time | 41 |
cells via | 41 |
stem cell | 40 |
mass gatherings | 40 |
full genome | 40 |
transmission among | 40 |
cytokine production | 40 |
protein structure | 40 |
animal reservoirs | 40 |
first confirmed | 40 |
highest number | 40 |
serine proteases | 40 |
analysis using | 40 |
host interactions | 40 |
potent neutralizing | 40 |
highly potent | 40 |
hiv infection | 40 |
therapeutic option | 40 |
coronavirus neutralizing | 40 |
analysis based | 40 |
per year | 40 |
inflammatory cells | 40 |
renal replacement | 40 |
nucleotide sequence | 40 |
among hcws | 40 |
ng ml | 40 |
severe influenza | 40 |
acute pneumonia | 40 |
vivo studies | 40 |
chloroquine effectively | 40 |
cov may | 40 |
nasopharyngeal swabs | 40 |
drug development | 40 |
retrospective analysis | 40 |
disease response | 40 |
pregnant woman | 40 |
recovery delay | 40 |
cov viral | 40 |
cov spread | 40 |
recent insights | 40 |
therapeutic remdesivir | 40 |
asymptomatic infections | 39 |
coronavirus among | 39 |
cov nucleocapsid | 39 |
fusion inhibitors | 39 |
young children | 39 |
clinical research | 39 |
way anova | 39 |
measles virus | 39 |
seafood market | 39 |
nasal discharge | 39 |
whole blood | 39 |
camel herd | 39 |
rna replication | 39 |
crystal structures | 39 |
combination lopinavir | 39 |
virus neutralisation | 39 |
batcov hku | 39 |
high morbidity | 39 |
influenza pandemic | 39 |
face masks | 39 |
environmental contamination | 39 |
information regarding | 39 |
dmv formation | 39 |
passive immunotherapy | 39 |
virus load | 39 |
fc protein | 39 |
transient lower | 39 |
binding protein | 39 |
molecular evolution | 39 |
severe lung | 39 |
clinical use | 39 |
angiotensin system | 39 |
hajj pilgrimage | 39 |
expressing cells | 39 |
herpes simplex | 39 |
immunocompromised patients | 39 |
endocytic pathway | 39 |
genus betacoronavirus | 39 |
serologic assays | 39 |
intravenous immunoglobulin | 39 |
unclear whether | 39 |
staphylococcus aureus | 39 |
fatal disease | 39 |
novel sars | 39 |
drug design | 39 |
less likely | 39 |
aged years | 39 |
protein induces | 39 |
high fever | 39 |
serological assays | 39 |
pseudovirus translocation | 39 |
interferon alpha | 39 |
lactate dehydrogenase | 38 |
viruses including | 38 |
binding motif | 38 |
rapid detection | 38 |
transcription pcr | 38 |
infected dromedary | 38 |
significantly increased | 38 |
cytopathic effects | 38 |
clinical outcome | 38 |
accession number | 38 |
i clinical | 38 |
virus excretion | 38 |
emerging pathogen | 38 |
significant increase | 38 |
pattern recognition | 38 |
recombinant proteins | 38 |
animal care | 38 |
international concern | 38 |
center experience | 38 |
early detection | 38 |
bat cells | 38 |
novel therapeutic | 38 |
miracle trial | 38 |
data indicate | 38 |
fusion core | 38 |
control animals | 38 |
chest pain | 38 |
newly emerging | 38 |
naturally occurring | 38 |
transcription factors | 38 |
infections caused | 38 |
commercially available | 38 |
neutralizing immunogenicity | 38 |
therapeutic potential | 38 |
antibody titres | 38 |
cellular receptors | 38 |
type iii | 38 |
disease pathogenesis | 38 |
syncytia formation | 38 |
serum sample | 38 |
ifn response | 38 |
dialysis patients | 38 |
therapeutic targets | 38 |
two decades | 38 |
mers virus | 38 |
coronavirus diseases | 38 |
effective antiviral | 38 |
health officials | 38 |
pegylated interferon | 38 |
rational design | 38 |
vesicular stomatitis | 38 |
cov genomes | 37 |
cause mild | 37 |
news consumption | 37 |
humanized mouse | 37 |
early diagnosis | 37 |
also used | 37 |
novel betacoronavirus | 37 |
gastrointestinal tract | 37 |
associated pneumonia | 37 |
antiviral agent | 37 |
cell tropism | 37 |
cov proteins | 37 |
sample collection | 37 |
nucleocapsid proteins | 37 |
viral spread | 37 |
determined using | 37 |
interferon antagonists | 37 |
highly immunogenic | 37 |
results show | 37 |
clinical progression | 37 |
stomatitis virus | 37 |
human rhinovirus | 37 |
median incubation | 37 |
ic value | 37 |
may help | 37 |
plasmacytoid dendritic | 37 |
last years | 37 |
noninvasive ventilation | 37 |
natural infection | 37 |
three groups | 37 |
oral route | 37 |
ace receptors | 37 |
compassionate use | 37 |
ribavirin improves | 37 |
predict pdf | 37 |
viral vector | 37 |
underlying medical | 37 |
highly effective | 37 |
hr domain | 37 |
growth factor | 37 |
coronaviridae family | 37 |
phylogenetic analyses | 37 |
serological evidence | 37 |
slaughterhouse workers | 37 |
coronavirus pathogenesis | 37 |
traditional media | 37 |
viral attachment | 37 |
cov activity | 37 |
cd cd | 37 |
serial interval | 37 |
mice showed | 37 |
syndrome corona | 37 |
zoonotic disease | 37 |
care units | 37 |
also demonstrated | 37 |
respiratory system | 37 |
ct findings | 37 |
zoonotic viruses | 37 |
sectional study | 37 |
major outbreak | 36 |
cell viability | 36 |
close relative | 36 |
laboratory animals | 36 |
negative controls | 36 |
human bocavirus | 36 |
transmission routes | 36 |
dnsp mutant | 36 |
korean society | 36 |
control strategies | 36 |
prefusion conformation | 36 |
lung cells | 36 |
mildly symptomatic | 36 |
antibody levels | 36 |
literature update | 36 |
cov macro | 36 |
isothermal amplification | 36 |
maximum likelihood | 36 |
respiratory secretions | 36 |
virus isolated | 36 |
naturally infected | 36 |
health response | 36 |
healthcare professionals | 36 |
significantly different | 36 |
index cases | 36 |
different species | 36 |
antiviral responses | 36 |
spectrum antivirals | 36 |
cl protease | 36 |
replication complex | 36 |
human bronchial | 36 |
mva mers | 36 |
attack rates | 36 |
tissue samples | 36 |
therapeutic interventions | 36 |
early transmission | 36 |
binding sites | 36 |
oxygen therapy | 36 |
cell activation | 36 |
infectious dose | 36 |
lysis buffer | 36 |
infected cases | 36 |
lung inflammation | 36 |
randomised controlled | 36 |
hospital admission | 36 |
chronic hepatitis | 36 |
potential target | 36 |
patients presenting | 36 |
monkeypox virus | 36 |
vaccinated animals | 36 |
canonical cleavage | 36 |
heparan sulfate | 36 |
gene sequences | 36 |
lung damage | 36 |
enhanced disease | 36 |
three camel | 36 |
informed consent | 36 |
human antibodies | 36 |
human angiotensin | 36 |
four genera | 36 |
using real | 36 |
small sample | 36 |
seven days | 36 |
culture medium | 36 |
serologic testing | 36 |
like cov | 36 |
umbilical cord | 36 |
pcr results | 36 |
kindly provided | 36 |
swab specimens | 35 |
rectal swabs | 35 |
confi rmed | 35 |
high degree | 35 |
pneumonia associated | 35 |
optimal control | 35 |
healthy adults | 35 |
blood donors | 35 |
time point | 35 |
mainland china | 35 |
neurological manifestations | 35 |
vector vaccine | 35 |
inflammatory cytokine | 35 |
three different | 35 |
women infected | 35 |
equine encephalitis | 35 |
virus clearance | 35 |
like covs | 35 |
animal covs | 35 |
systematic reviews | 35 |
include fever | 35 |
dromedary mers | 35 |
clinical development | 35 |
cellular entry | 35 |
natural products | 35 |
chinese center | 35 |
preliminary report | 35 |
much lower | 35 |
vaccine induces | 35 |
order nidovirales | 35 |
many cases | 35 |
many studies | 35 |
simplex virus | 35 |
clinical specimens | 35 |
confirmed patients | 35 |
important roles | 35 |
terminal region | 35 |
molecular epidemiology | 35 |
negative results | 35 |
per mouse | 35 |
clinical isolates | 35 |
case definitions | 35 |
prediction model | 35 |
blood cell | 35 |
transmission events | 35 |
asymptomatic patients | 35 |
chronic kidney | 35 |
cells using | 35 |
cov hku | 35 |
third week | 35 |
virus may | 35 |
infectious mers | 35 |
pathological findings | 35 |
neuraminidase inhibitors | 35 |
medical countermeasures | 35 |
molecular biology | 35 |
laboratory diagnosis | 35 |
pulmonary edema | 35 |
hdpp mice | 35 |
inhibit viral | 35 |
st century | 35 |
probable sars | 35 |
diff erent | 35 |
vaccine platforms | 35 |
genome replication | 35 |
transfected cells | 34 |
use authorization | 34 |
specific neutralizing | 34 |
log tcid | 34 |
close proximity | 34 |
angiotensinconverting enzyme | 34 |
yellow fever | 34 |
major role | 34 |
genetic characterization | 34 |
genomic study | 34 |
cases among | 34 |
familial cluster | 34 |
drug combinations | 34 |
open access | 34 |
exceptionally potent | 34 |
organ dysfunction | 34 |
pathogenic avian | 34 |
years later | 34 |
natural host | 34 |
recombinant receptor | 34 |
related bat | 34 |
pandemic risk | 34 |
mice expressing | 34 |
first two | 34 |
emerg infect | 34 |
mers vaccines | 34 |
viral protein | 34 |
different mers | 34 |
polyclonal antibodies | 34 |
influenza vaccination | 34 |
detection limit | 34 |
inflammatory cell | 34 |
mild disease | 34 |
community acquired | 34 |
antibodies targeting | 34 |
four patients | 34 |
cultured cells | 34 |
glass opacities | 34 |
killer cell | 34 |
blood products | 34 |
aged mice | 34 |
treatment group | 34 |
international health | 34 |
fatal outcome | 34 |
polyclonal antibody | 34 |
cov papain | 34 |
release syndrome | 34 |
causes transient | 34 |
university hospital | 34 |
cov testing | 34 |
transmembrane protease | 34 |
syndrome cov | 34 |
mesenchymal stem | 34 |
avian iavs | 34 |
potential conflicts | 34 |
different countries | 34 |
genome structure | 34 |
coronavirus indicating | 33 |
standard deviation | 33 |
cov patient | 33 |
epidemic potential | 33 |
camels mers | 33 |
risk perceptions | 33 |
immune cell | 33 |
inactivated virus | 33 |
less severe | 33 |
small intestine | 33 |
stool samples | 33 |
remdesivir treatment | 33 |
comparative therapeutic | 33 |
white blood | 33 |
class ii | 33 |
age group | 33 |
genomic sequence | 33 |
viral challenge | 33 |
pseudoparticle virus | 33 |
assays reveal | 33 |
among dromedary | 33 |
medical institutions | 33 |
time course | 33 |
airborne precautions | 33 |
cytokine chemokine | 33 |
china clinical | 33 |
related coronaviruses | 33 |
rabies virus | 33 |
two independent | 33 |
reduces virus | 33 |
livestock species | 33 |
tissue distribution | 33 |
patients hospitalized | 33 |
medical research | 33 |
tohuman transmission | 33 |
current covid | 33 |
induced dimerization | 33 |
chronic diseases | 33 |
psychological impact | 33 |
dendritic cell | 33 |
coronaviruses sars | 33 |
health security | 33 |
high rate | 33 |
viral polymerase | 33 |
viral particle | 33 |
patients without | 33 |
respiratory tracts | 33 |
may explain | 33 |
clinical samples | 33 |
lavage fluid | 33 |
studies suggest | 33 |
adapted mers | 33 |
underlying diseases | 33 |
medical city | 33 |
conjugated anti | 33 |
developing countries | 33 |
reported hand | 33 |
sputum samples | 33 |
possible cause | 33 |
reduced mers | 33 |
virus hemagglutinin | 32 |
domestic livestock | 32 |
among pilgrims | 32 |
animal hosts | 32 |
different cell | 32 |
newly emerged | 32 |
novel corona | 32 |
severe infection | 32 |
commons attribution | 32 |
day postinfection | 32 |
civet cats | 32 |
future outbreaks | 32 |
protease activity | 32 |
new zealand | 32 |
adaptive immunity | 32 |
immunofluorescence assay | 32 |
different animal | 32 |
emergency committee | 32 |
mild upper | 32 |
control guidelines | 32 |
well established | 32 |
humoral immunity | 32 |
guinea pig | 32 |
beta coronavirus | 32 |
high proportion | 32 |
cell cycle | 32 |
social support | 32 |
inactivated vaccine | 32 |
health threat | 32 |
first report | 32 |
protective immune | 32 |
syndrome coronaviruses | 32 |
mers vaccine | 32 |
molecular dynamics | 32 |
two distinct | 32 |
secondary antibody | 32 |
korean mers | 32 |
copies per | 32 |
transmission risk | 32 |
international license | 32 |
lethal mers | 32 |
emerging diseases | 32 |
coronavirus infectious | 32 |
lower levels | 32 |
treated animals | 32 |
neutralisation assays | 32 |
entry inhibitors | 32 |
local health | 32 |
infectious agents | 32 |
body fluids | 32 |
underlying conditions | 32 |
sequence homology | 32 |
throat swab | 32 |
virus rna | 32 |
analysis revealed | 32 |
also shown | 32 |
nucleoside analog | 32 |
care providers | 32 |
flow rate | 32 |
clinical efficacy | 32 |
avian infectious | 32 |
like disease | 32 |
healthcare facility | 32 |
antiviral gs | 32 |
drug resistance | 32 |
zoonotic infections | 32 |
cov using | 32 |
become infected | 32 |
pilot study | 31 |
large numbers | 31 |
five patients | 31 |
study mers | 31 |
invasive mechanical | 31 |
acid sequences | 31 |
serological tests | 31 |
using microneutralisation | 31 |
cov exposure | 31 |
considered statistically | 31 |
hyperimmune plasma | 31 |
host proteins | 31 |
new drug | 31 |
mrna expression | 31 |
pathogenic viruses | 31 |
descriptive genomic | 31 |
rabbit anti | 31 |
mucosal immune | 31 |
sialic acids | 31 |
ii clinical | 31 |
essential role | 31 |
protein interactions | 31 |
virus detection | 31 |
hospital staff | 31 |
mild cases | 31 |
virus outbreak | 31 |
human isolates | 31 |
infection clinical | 31 |
may require | 31 |
mouse anti | 31 |
ace protein | 31 |
healthy individuals | 31 |
european bats | 31 |
signal peptide | 31 |
pneumonia development | 31 |
viruses related | 31 |
sequence similarity | 31 |
int csr | 31 |
study using | 31 |
old male | 31 |
fluorescence intensity | 31 |
reduction neutralization | 31 |
positive cases | 31 |
three patients | 31 |
animal market | 31 |
patients receiving | 31 |
investigation middle | 31 |
virus neutralization | 31 |
hdpp transgenic | 31 |
mhc class | 31 |
clinical benefit | 31 |
associated outbreaks | 31 |
interferon antagonist | 31 |
host responses | 31 |
international spread | 31 |
infection middle | 31 |
incubation periods | 31 |
mutant mers | 31 |
scientific community | 31 |
lung epithelial | 31 |
additional file | 31 |
operating room | 31 |
plasma treatment | 31 |
clinical manifestation | 31 |
major livestock | 30 |
promising results | 30 |
disseminated intravascular | 30 |
cell type | 30 |
likely due | 30 |
obtained using | 30 |
camel sera | 30 |
crisis management | 30 |
acid substitutions | 30 |
epidemiological assessment | 30 |
total rna | 30 |
independent experiments | 30 |
palm civet | 30 |
patient exposure | 30 |
nsp protein | 30 |
aerosol transmission | 30 |
comprehensive review | 30 |
genetic analysis | 30 |
ultrastructural findings | 30 |
day survival | 30 |
gold standard | 30 |
severe clinical | 30 |
years ago | 30 |
per group | 30 |
wild animal | 30 |
although mers | 30 |
significant reduction | 30 |
will need | 30 |
treatment effects | 30 |
risk group | 30 |
community transmission | 30 |
ncov spike | 30 |
results indicated | 30 |
international severe | 30 |
final concentration | 30 |
cov emerged | 30 |
expressing human | 30 |
active surveillance | 30 |
ct imaging | 30 |
natural history | 30 |
vital role | 30 |
previously published | 30 |
samsung medical | 30 |
bat cell | 30 |
vaccine based | 30 |
family contacts | 30 |
cell rna | 30 |
related deaths | 30 |
higher affinity | 30 |
mediated entry | 30 |
huanan seafood | 30 |
korea outbreak | 30 |
data regarding | 30 |
study aimed | 30 |
surface glycoprotein | 30 |
ebola outbreak | 30 |
days later | 30 |
mers crisis | 30 |
lethal infection | 30 |
nosocomial outbreak | 30 |
inactivated mers | 30 |
catalytic activity | 30 |
glucocorticoid therapy | 30 |
transmission characteristics | 30 |
substrate specificity | 30 |
ncov outbreak | 30 |
korean government | 30 |
climate change | 30 |
antiviral remdesivir | 30 |
indicating person | 30 |
research center | 30 |
many countries | 30 |
epidemiological studies | 30 |
pcr tests | 30 |
cell infiltration | 30 |
throughput screening | 30 |
transmission rate | 30 |
per site | 30 |
transmission route | 30 |
potent antiviral | 30 |
clinical laboratories | 30 |
canary islands | 30 |
using two | 30 |
first week | 30 |
strongly inhibited | 30 |
south africa | 30 |
insectivorous bats | 30 |
financial support | 30 |
south china | 30 |
cov orf | 30 |
endemic areas | 29 |
current outbreak | 29 |
epi isl | 29 |
average number | 29 |
poor prognosis | 29 |
detected using | 29 |
airway epithelium | 29 |
isolation room | 29 |
wuhan city | 29 |
therapeutic strategy | 29 |
fully understood | 29 |
study population | 29 |
symptoms including | 29 |
enhanced ppe | 29 |
severe symptoms | 29 |
potently inhibits | 29 |
viral genomes | 29 |
long time | 29 |
induced acute | 29 |
infection caused | 29 |
spike glycoproteins | 29 |
viral nucleic | 29 |
betacoronavirus emc | 29 |
influenza vaccines | 29 |
potential source | 29 |
cell proteases | 29 |
commons license | 29 |
outbreak occurred | 29 |
genomic sequences | 29 |
using graphpad | 29 |
neutralization tests | 29 |
serum levels | 29 |
ct scans | 29 |
fusion inhibitory | 29 |
syndrome clinical | 29 |
natural hosts | 29 |
rapid spread | 29 |
fi rst | 29 |
eastern mediterranean | 29 |
peptidase iv | 29 |
human influenza | 29 |
mouse dpp | 29 |
control mice | 29 |
neutralization activity | 29 |
host tropism | 29 |
lethal challenge | 29 |
nucleoside analogues | 29 |
study demonstrated | 29 |
version posted | 29 |
siq model | 29 |
ill covid | 29 |
heart failure | 29 |
therapeutic intervention | 29 |
mers pseudovirus | 29 |
potential targets | 29 |
molecular mechanism | 29 |
urine samples | 29 |
cov plp | 29 |
kidney failure | 29 |
phase clinical | 29 |
obstructive pulmonary | 29 |
current pandemic | 29 |
recent report | 29 |
passive transfer | 29 |
african countries | 29 |
hct intersection | 29 |
health systems | 29 |
clinical testing | 29 |
bone marrow | 29 |
host susceptibility | 29 |
risk groups | 29 |
cause disease | 29 |
infected cell | 29 |
diagnostic test | 29 |
single inoculum | 29 |
disease associated | 29 |
coronavirus seroprevalence | 29 |
supervisor support | 29 |
protein data | 29 |
take place | 29 |
endemic human | 29 |
coronavirus family | 29 |
asymptomatic mers | 29 |
cov positive | 29 |
antibiotic resistance | 29 |
intestinal tract | 29 |
stimulated gene | 29 |
affected areas | 29 |
convalescent sera | 29 |
regulatory factor | 29 |
recent outbreak | 29 |
aspartate aminotransferase | 29 |
animal welfare | 29 |
first days | 28 |
deficient mice | 28 |
ifn signaling | 28 |
inoculated dromedary | 28 |
air travel | 28 |
novel mammalian | 28 |
erasmus medical | 28 |
therapeutic development | 28 |
emerging virus | 28 |
mice transgenic | 28 |
outbreak study | 28 |
interhuman transmissibility | 28 |
job stress | 28 |
nuclear import | 28 |
remains unknown | 28 |
traumatic stress | 28 |
primary middle | 28 |
zippered er | 28 |
data set | 28 |
identifi ed | 28 |
human emergence | 28 |
affected region | 28 |
several factors | 28 |
medical students | 28 |
hospital stay | 28 |
antibody tests | 28 |
health regulations | 28 |
treating covid | 28 |
adults hospitalized | 28 |
treatment outcomes | 28 |
compound library | 28 |
intravascular coagulation | 28 |
previously identified | 28 |
wide variety | 28 |
corticosteroid use | 28 |
animal coronaviruses | 28 |
tracheal aspirates | 28 |
nucleoside analogue | 28 |
limited data | 28 |
disaster management | 28 |
cycle threshold | 28 |
broadly neutralizing | 28 |
diagnostic methods | 28 |
murine model | 28 |
error bars | 28 |
animal host | 28 |
health interventions | 28 |
genetic material | 28 |
human primate | 28 |
eff ects | 28 |
health crisis | 28 |
infecting humans | 28 |
com scientificdata | 28 |
cause respiratory | 28 |
regression model | 28 |
sequence divergence | 28 |
including fever | 28 |
infection rate | 28 |
patient rooms | 28 |
ifn induction | 28 |
mediated activation | 28 |
electron density | 28 |
iu ml | 28 |
human clinical | 28 |
autoimmune diseases | 28 |
nuclear factor | 28 |
reported case | 28 |
zoonotic pathogens | 28 |
old tg | 28 |
cov fusion | 28 |
european centre | 28 |
therapeutic drugs | 28 |
cov investigation | 28 |
cell receptors | 28 |
one case | 28 |
coronavirus open | 28 |
patients developed | 28 |
respiratory epithelial | 28 |
vaccine reduces | 28 |
pulmonary pathology | 28 |
new world | 28 |
data bank | 28 |
diagnostic testing | 28 |
first detected | 28 |
immunological responses | 28 |
preclinical studies | 28 |
ongoing clinical | 28 |
chronic obstructive | 28 |
lethal respiratory | 28 |
transcriptase polymerase | 28 |
membrane formation | 27 |
health workers | 27 |
elderly patients | 27 |
recombinant adenovirus | 27 |
infected humans | 27 |
antiviral treatments | 27 |
treated group | 27 |
hajj season | 27 |
pregnant patients | 27 |
highly sensitive | 27 |
host gene | 27 |
continuous variables | 27 |
cov mouse | 27 |
length infectious | 27 |
cov uses | 27 |
novel humanized | 27 |
categorical variables | 27 |
may increase | 27 |
epidemiological outbreak | 27 |
genes encoding | 27 |
laboratory confirmed | 27 |
raw camel | 27 |
coronavirus strains | 27 |
th percentile | 27 |
hyaline membrane | 27 |
protein receptor | 27 |
antiviral innate | 27 |
lesser extent | 27 |
cases occurred | 27 |
following infection | 27 |
blood mononuclear | 27 |
first line | 27 |
well plate | 27 |
samples obtained | 27 |
local government | 27 |
structural analysis | 27 |
th responses | 27 |
causing sars | 27 |
bibliometric analysis | 27 |
wet markets | 27 |
ec value | 27 |
triple combination | 27 |
bacterial infections | 27 |
surface expression | 27 |
older adults | 27 |
van doremalen | 27 |
cov shedding | 27 |
three days | 27 |
hospitalized children | 27 |
included patients | 27 |
nhp models | 27 |
treated patients | 27 |
educational programs | 27 |
scientific research | 27 |
underlying comorbidities | 27 |
bl loop | 27 |
critical illness | 27 |
attenuated vaccines | 27 |
infection consortium | 27 |
like illness | 27 |
previous sars | 27 |
infection model | 27 |
transmission occurred | 27 |
nosocomial infections | 27 |
high expression | 27 |
infected individual | 27 |
inflammatory monocyte | 27 |
per ml | 27 |
pneumonia patients | 27 |
readily available | 27 |
i interferons | 27 |
inhibitory effects | 27 |
mers epidemic | 27 |
days postinfection | 27 |
several limitations | 27 |
previous work | 27 |
coronavirus detection | 27 |
findings indicate | 27 |
culture supernatants | 27 |
emergency response | 27 |
three viruses | 27 |
high sensitivity | 27 |
urchin egg | 27 |
final manuscript | 27 |
study period | 27 |
large outbreak | 27 |
detect mers | 27 |
studies will | 27 |
novel bat | 27 |
cases per | 27 |
data collected | 27 |
sequence data | 27 |
receptor blockers | 27 |
treatment option | 27 |
evidence suggests | 27 |
outer membrane | 27 |
based assay | 27 |
stimulated genes | 27 |
pcr method | 27 |
disease enhancement | 27 |
signal transduction | 27 |
still unknown | 27 |
health concept | 27 |
will require | 27 |
pilgrims returning | 27 |
blot analysis | 27 |
using mers | 26 |
immune activation | 26 |
first human | 26 |
equine coronavirus | 26 |
drug treatment | 26 |
short time | 26 |
unlike sars | 26 |
potential vaccine | 26 |
glass opacity | 26 |
outbreak following | 26 |
different environmental | 26 |
attenuated vaccine | 26 |
among hajj | 26 |
differential expression | 26 |
vaccines based | 26 |
conducted using | 26 |
macrophage responses | 26 |
mediated endocytosis | 26 |
two days | 26 |
cord blood | 26 |
high rates | 26 |
ace inhibitors | 26 |
gel electrophoresis | 26 |
infected persons | 26 |
plate reader | 26 |
health system | 26 |
short period | 26 |
mm hepes | 26 |
applied biosystems | 26 |
pro enzymes | 26 |
lassa fever | 26 |
published studies | 26 |
community outbreak | 26 |
proteolytic activation | 26 |
camelus dromedarius | 26 |
coronavirus human | 26 |
gold nanoparticles | 26 |
higher viral | 26 |
situation report | 26 |
two human | 26 |
although many | 26 |
antiviral properties | 26 |
genus deltacoronavirus | 26 |
reported among | 26 |
study revealed | 26 |
first patient | 26 |
information sharing | 26 |
recombinant viruses | 26 |
serological testing | 26 |
hcov infections | 26 |
van der | 26 |
pseudovirus infection | 26 |
respiratory epithelium | 26 |
camel herds | 26 |
eff ective | 26 |
pcr test | 26 |
liver enzymes | 26 |
serial dilutions | 26 |
renal impairment | 26 |
specific treatment | 26 |
also called | 26 |
viral etiology | 26 |
respiratory illnesses | 26 |
possible role | 26 |
human primary | 26 |
total cases | 26 |
high concentrations | 26 |
chest radiography | 26 |
virus glycoprotein | 26 |
based drug | 26 |
will provide | 26 |
previous coronavirus | 26 |
th response | 26 |
controlled clinical | 26 |
among children | 26 |
positive correlation | 26 |
mers infections | 26 |
often used | 26 |
recombinant human | 26 |
coding sequence | 26 |
retrospective studies | 26 |
case studies | 26 |
species severe | 26 |
large outbreaks | 26 |
presenting cells | 26 |
another zoonotic | 26 |
zoonotic origins | 26 |
infection models | 26 |
transmission via | 26 |
induced lung | 26 |
epidemiological findings | 26 |
induces severe | 26 |
one group | 26 |
significant role | 26 |
recombinant modified | 26 |
primary mers | 26 |
ii transmembrane | 26 |
reverse genetic | 26 |
camostat mesylate | 26 |
human mab | 26 |
coronavirus strain | 26 |
membrane structures | 26 |
overall mortality | 26 |
like bat | 26 |
adenosine deaminase | 26 |
increased mortality | 26 |
alanine aminotransferase | 26 |
therapeutic treatment | 26 |
clinically approved | 26 |
binding interface | 26 |
also important | 26 |
develop severe | 26 |
coronavirus genomes | 26 |
health measures | 26 |
patients died | 26 |
previous outbreaks | 26 |
swine acute | 26 |
cov rrt | 26 |
receptor dipeptidyl | 26 |
korea mers | 25 |
inflammatory bowel | 25 |
showed similar | 25 |
first described | 25 |
faecal samples | 25 |
clinical treatment | 25 |
protein binds | 25 |
elisa kit | 25 |
online version | 25 |
medrxiv preprint | 25 |
animal markets | 25 |
therapeutic target | 25 |
molecular patterns | 25 |
suspected patients | 25 |
respiratory coronaviruses | 25 |
hospital patients | 25 |
virtual screening | 25 |
four human | 25 |
among sars | 25 |
potential mers | 25 |
acid detection | 25 |
studies conducted | 25 |
known human | 25 |
expression plasmids | 25 |
pore channel | 25 |
phase trial | 25 |
develop vaccines | 25 |
porcine respiratory | 25 |
demographic characteristics | 25 |
human pathogens | 25 |
prostate cancer | 25 |
ml penicillin | 25 |
studies also | 25 |
coronavirus main | 25 |
lymph node | 25 |
glycan probe | 25 |
betacoronavirus causing | 25 |
specifically targeting | 25 |
kinase inhibitors | 25 |
may affect | 25 |
cell signaling | 25 |
higher concentrations | 25 |
vero cell | 25 |
blood vessels | 25 |
million people | 25 |
liver injury | 25 |
cardiac injury | 25 |
effective therapeutic | 25 |
secondary transmission | 25 |
respiratory pathogen | 25 |